stars 1 stars 2 stars 3

Physiogenex is a leading preclinical research organization (CRO) specializing in metabolic disorders such as diabetes, insulin resistance, obesity, fatty liver (NASH / NAFLD), dyslipidemia, atherosclerosis and cardiovascular complications. We provide: - Classical and proprietary diet-induced in vivo models - Innovative in-house techniques (RCT) and gold standard methods (glucose clamps with radiolabelled tracers, …) - In vivo preclinical imaging services Our models and technologies are customized and we deliver unparalleled scientific expertise for R&D, preclinical development, post-marketing studies and drug repositioning. We provide both the biopharmaceutical and nutraceutical companies with optimal and reliable solutions for successful strategic decision-making.

Physiogenex Questions

The Physiogenex annual revenue was $5 million in 2026.

François Briand is the Director - Research and Business Development of Physiogenex.

22 people are employed at Physiogenex.

Physiogenex is based in Escalquens, Occitania.

The NAICS codes for Physiogenex are [54171, 541713, 5417, 54, 541].

The SIC codes for Physiogenex are [87, 873].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users